Stockpolly
Search
STTK · NASDAQ · Biotechnology

Shattuck Labs (STTK)

Develops DR3-blocking antibodies for inflammatory and immune-mediated diseases.

$6.71
Pre-market−0.20 (−2.89%)
At close$6.91(+0.58%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue111230001000
Cost of revenue2411110118010
Gross profit−2400120−1−1−70−10
5192024202013124131516
Research & development241516191615109891112
534554444454
Selling & marketing0−1−1000000000
General & administrative545554444454
Other expenses−2400−1−10−1−1−80−10
Operating income−29−19−20−23−18−20−14−13−11−13−16−16
112111111111
Interest income010005000011
Other non-operating income0−1−2−1−1−1−1−1−1−1−1−1
Income before tax−28−18−19−22−17−19−14−12−10−13−15−15
Net income from continuing operations−28−18−19−22−17−19−14−12−10−13−15−15
Net income−28−18−19−22−17−19−14−12−10−13−15−15
EPS, basic−$0.65−$0.41−$0.37−$0.42−$0.33−$0.37−$0.27−$0.24−$0.14−$0.12−$0.13−$0.12
EPS, diluted−$0.65−$0.41−$0.37−$0.42−$0.33−$0.37−$0.27−$0.24−$0.14−$0.12−$0.13−$0.12
Weighted average shares, basic424351515151515172104112130
Weighted average shares, diluted424351515151515172104112130
EBITDA−28−17−18−21−16−18−13−12−9−12−14−14
Depreciation & amortization111111111111
EBIT−29−18−19−22−17−19−14−12−10−13−15−15